View Financial HealthCovalon Technologies 配当と自社株買い配当金 基準チェック /26Covalon Technologies配当を支払う会社であり、現在の利回りは7.81%です。主要情報7.8%配当利回り-0.09%バイバック利回り総株主利回り-0.09%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).すべての更新を表示Recent updatesお知らせ • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026お知らせ • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.お知らせ • Dec 04Covalon Technologies Ltd. to Report Q4, 2025 Results on Dec 11, 2025Covalon Technologies Ltd. announced that they will report Q4, 2025 results Pre-Market on Dec 11, 2025お知らせ • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).お知らせ • Sep 26Covalon Technologies Ltd. Presents Evidence-Backed Innovations Making A Difference for Critically Ill Children At AphonCovalon Technologies Ltd. presented evidence-backed innovations making a difference for critically ill Children At Aphon. The company announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25-27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children's Hospital at Montefiore describing how the hospital's experience with VALGuard®? Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI's (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard®? and highlight its role in protecting vulnerable pediatric patients. In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear®? silicone dressing, used as a cover for primary dressings, greatly helped reduce unplanned dressing changes caused by soiling, leaks, or contamination. Avoiding unplanned dressing changes translates into measurable cost savings for hospitals and reduced workload for nurses, while preserving skin integrity for patients who already face intensive therapies. These findings underscore the dual impact of Covalon's portfolio which is designed to improve patient outcomes while creating measurable efficiencies for hospitals seeking to optimize both quality of care and economic performance. At APHON, Covalon will showcase the breadth of its vascular access portfolio, including: VALGuard®? Line Guard - A transparent, single-use barrier designed to cover and protect IV line connections and catheter hubs from external contaminants, including body fluids and secretions that can lead to infection. VALGuard®? incorporates a unique quick-release pull strip that enables fast access to the line for clinicians. CovaClear®? Dressings - A family of versatile gentle-to-skin silicone dressings that can be used as a primary IV securement dressing or as a protective cover over existing primary dressings. By helping reduce unplanned primary IV dressing changes caused by soiled, fluid leaks, or external contamination, CovaClear®? helps customers save money on wasted supplies, reduce nursing workload, and supports efforts to preserve patient skin integrity. IV Clear®? Dressings - Afamily of transparent IV securement dressings that combine gentle-to-skin silicone adhesive technology with edge-to-edge coverage of chlorhexidine and silver for antimicrobial protection. IV Clear®? provides complete transparency to the insertion site, supporting routine assessment and better line management. The company's solutions are designed not only to support better outcomes for patients but also to provide hospitals with measurable savings and long-term value.お知らせ • Sep 24Covalon Technologies Ltd. Announces Board ChangesCovalon Technologies Ltd. announced that Mr. Abe Schwartz has been elected Chair of the Board of the Company. Mr. Schwartz succeeds Mr. Amir Boloor, who has decided to step down as a director and Executive Chair of Covalon with effect September 23, 2025. Mr. Schwartz, a member of the Covalon Board since 2008, has previously served as Covalon Board Chair from 2012 until 2020. He has been a successful Healthcare and I.T. industry entrepreneur, CEO and investor over the past 50 years and is Covalon’s largest shareholder.お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2025 Results on Aug 21, 2025Covalon Technologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Aug 21, 2025お知らせ • May 27Covalon Technologies Ltd. Announces New Clinical Research Evaluating Vascular Access Line GuardCovalon Technologies Ltd. announced that exciting results from a clinical study evaluating the use of its VALGuard Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall - September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.お知らせ • May 21Covalon Technologies Ltd. to Report Q2, 2025 Results on May 28, 2025Covalon Technologies Ltd. announced that they will report Q2, 2025 results Pre-Market on May 28, 2025お知らせ • Feb 14Covalon Technologies Ltd. to Report Q1, 2025 Results on Feb 21, 2025Covalon Technologies Ltd. announced that they will report Q1, 2025 results Pre-Market on Feb 21, 2025お知らせ • Jan 06Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025.お知らせ • Dec 19Covalon Technologies Ltd. to Report Q4, 2024 Results on Jan 07, 2025Covalon Technologies Ltd. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Jan 07, 2025お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2024 Results on Aug 21, 2024Covalon Technologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Aug 21, 2024お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2024 Results on May 29, 2024Covalon Technologies Ltd. announced that they will report Q2, 2024 results Pre-Market on May 29, 2024お知らせ • Jan 26+ 1 more updateCovalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - OperationsCovalon Technologies Ltd. announced that Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.お知らせ • Dec 21Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024.お知らせ • Oct 12Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in ChicagoCovalon Technologies Ltd. announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from October 12 to October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence. Covalon's patented infection prevention and wound care products include: VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.お知らせ • Sep 28Covalon Technologies Ltd. Announces Chief Executive Officer ChangesCovalon Technologies Ltd. appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer, effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO. Mr. Boloor succeeds Brian Pedlar, who will remain on Covalon’s Board of Directors.お知らせ • Sep 27Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent DirectorCovalon Technologies Ltd. appointed Joseph Cordiano to serve as lead independent director.お知らせ • Aug 15Covalon Technologies Ltd. to Report Q3, 2023 Results on Aug 16, 2023Covalon Technologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Aug 16, 2023お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2023 Results on May 25, 2023Covalon Technologies Ltd. announced that they will report Q2, 2023 results Pre-Market on May 25, 2023お知らせ • Feb 18Covalon Technologies Ltd. to Report Q1, 2023 Results on Feb 23, 2023Covalon Technologies Ltd. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 23, 2023お知らせ • Jan 24Covalon Technologies Ltd. to Report Q4, 2022 Results on Jan 25, 2023Covalon Technologies Ltd. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 25, 2023決済の安定と成長配当データの取得安定した配当: CVAL.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CVAL.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Covalon Technologies 配当利回り対市場CVAL.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CVAL.F)7.8%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.5%アナリスト予想 (CVAL.F) (最長3年)n/a注目すべき配当: CVAL.Fの配当金 ( 7.81% ) はUS市場の配当金支払者の下位 25% ( 1.39% ) よりも高くなっています。高配当: CVAL.Fの配当金 ( 7.81% ) はUS市場 ( 4.21% ) の配当支払者の中で上位 25% に入っています。株主への利益配当収益カバレッジ: CVAL.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CVAL.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 05:10終値2026/05/05 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Covalon Technologies Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Andre UddinResearch Capital Corporation
お知らせ • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).
お知らせ • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026
お知らせ • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.
お知らせ • Dec 04Covalon Technologies Ltd. to Report Q4, 2025 Results on Dec 11, 2025Covalon Technologies Ltd. announced that they will report Q4, 2025 results Pre-Market on Dec 11, 2025
お知らせ • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).
お知らせ • Sep 26Covalon Technologies Ltd. Presents Evidence-Backed Innovations Making A Difference for Critically Ill Children At AphonCovalon Technologies Ltd. presented evidence-backed innovations making a difference for critically ill Children At Aphon. The company announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25-27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children's Hospital at Montefiore describing how the hospital's experience with VALGuard®? Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI's (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard®? and highlight its role in protecting vulnerable pediatric patients. In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear®? silicone dressing, used as a cover for primary dressings, greatly helped reduce unplanned dressing changes caused by soiling, leaks, or contamination. Avoiding unplanned dressing changes translates into measurable cost savings for hospitals and reduced workload for nurses, while preserving skin integrity for patients who already face intensive therapies. These findings underscore the dual impact of Covalon's portfolio which is designed to improve patient outcomes while creating measurable efficiencies for hospitals seeking to optimize both quality of care and economic performance. At APHON, Covalon will showcase the breadth of its vascular access portfolio, including: VALGuard®? Line Guard - A transparent, single-use barrier designed to cover and protect IV line connections and catheter hubs from external contaminants, including body fluids and secretions that can lead to infection. VALGuard®? incorporates a unique quick-release pull strip that enables fast access to the line for clinicians. CovaClear®? Dressings - A family of versatile gentle-to-skin silicone dressings that can be used as a primary IV securement dressing or as a protective cover over existing primary dressings. By helping reduce unplanned primary IV dressing changes caused by soiled, fluid leaks, or external contamination, CovaClear®? helps customers save money on wasted supplies, reduce nursing workload, and supports efforts to preserve patient skin integrity. IV Clear®? Dressings - Afamily of transparent IV securement dressings that combine gentle-to-skin silicone adhesive technology with edge-to-edge coverage of chlorhexidine and silver for antimicrobial protection. IV Clear®? provides complete transparency to the insertion site, supporting routine assessment and better line management. The company's solutions are designed not only to support better outcomes for patients but also to provide hospitals with measurable savings and long-term value.
お知らせ • Sep 24Covalon Technologies Ltd. Announces Board ChangesCovalon Technologies Ltd. announced that Mr. Abe Schwartz has been elected Chair of the Board of the Company. Mr. Schwartz succeeds Mr. Amir Boloor, who has decided to step down as a director and Executive Chair of Covalon with effect September 23, 2025. Mr. Schwartz, a member of the Covalon Board since 2008, has previously served as Covalon Board Chair from 2012 until 2020. He has been a successful Healthcare and I.T. industry entrepreneur, CEO and investor over the past 50 years and is Covalon’s largest shareholder.
お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2025 Results on Aug 21, 2025Covalon Technologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Aug 21, 2025
お知らせ • May 27Covalon Technologies Ltd. Announces New Clinical Research Evaluating Vascular Access Line GuardCovalon Technologies Ltd. announced that exciting results from a clinical study evaluating the use of its VALGuard Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall - September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.
お知らせ • May 21Covalon Technologies Ltd. to Report Q2, 2025 Results on May 28, 2025Covalon Technologies Ltd. announced that they will report Q2, 2025 results Pre-Market on May 28, 2025
お知らせ • Feb 14Covalon Technologies Ltd. to Report Q1, 2025 Results on Feb 21, 2025Covalon Technologies Ltd. announced that they will report Q1, 2025 results Pre-Market on Feb 21, 2025
お知らせ • Jan 06Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025.
お知らせ • Dec 19Covalon Technologies Ltd. to Report Q4, 2024 Results on Jan 07, 2025Covalon Technologies Ltd. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Jan 07, 2025
お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2024 Results on Aug 21, 2024Covalon Technologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Aug 21, 2024
お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2024 Results on May 29, 2024Covalon Technologies Ltd. announced that they will report Q2, 2024 results Pre-Market on May 29, 2024
お知らせ • Jan 26+ 1 more updateCovalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - OperationsCovalon Technologies Ltd. announced that Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.
お知らせ • Dec 21Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024.
お知らせ • Oct 12Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in ChicagoCovalon Technologies Ltd. announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from October 12 to October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence. Covalon's patented infection prevention and wound care products include: VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.
お知らせ • Sep 28Covalon Technologies Ltd. Announces Chief Executive Officer ChangesCovalon Technologies Ltd. appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer, effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO. Mr. Boloor succeeds Brian Pedlar, who will remain on Covalon’s Board of Directors.
お知らせ • Sep 27Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent DirectorCovalon Technologies Ltd. appointed Joseph Cordiano to serve as lead independent director.
お知らせ • Aug 15Covalon Technologies Ltd. to Report Q3, 2023 Results on Aug 16, 2023Covalon Technologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Aug 16, 2023
お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2023 Results on May 25, 2023Covalon Technologies Ltd. announced that they will report Q2, 2023 results Pre-Market on May 25, 2023
お知らせ • Feb 18Covalon Technologies Ltd. to Report Q1, 2023 Results on Feb 23, 2023Covalon Technologies Ltd. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 23, 2023
お知らせ • Jan 24Covalon Technologies Ltd. to Report Q4, 2022 Results on Jan 25, 2023Covalon Technologies Ltd. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 25, 2023